SPN-821 for Depression

This trial tests a new treatment called SPN-821, used alongside current antidepressants to determine if it helps adults with major depressive disorder (MDD) improve. The study compares SPN-821 to a placebo (a dummy pill with no active ingredients) to assess its effectiveness and safety. Individuals experiencing a major depressive episode for at least 8 weeks without significant improvement despite their current antidepressant treatment may be suitable candidates. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial requires you to stay on a stable dose of a specific antidepressant for at least 10 weeks before starting.

Research shows that SPN-821 is being tested for safety in treating major depressive disorder. In earlier studies, the same drug was generally well-tolerated by patients. Participants took it at a dose of 2400 mg every three days along with their usual antidepressants. Some side effects occurred, but most were mild and manageable.

SPN-821 works through a novel mechanism targeting depression with a different approach compared to typical antidepressants like SSRIs and SNRIs, which mainly focus on serotonin and norepinephrine pathways. SPN-821 is designed as an adjunctive treatment, meaning it's used in combination with existing antidepressants. This treatment involves taking oral tablets just twice a week, offering a convenient dosing schedule.

Initial findings suggest that SPN-821 can greatly reduce symptoms of depression in people with major depressive disorder. An earlier study showed that patients experienced a quick and noticeable drop in their depression levels when taking SPN-821. The treatment was well-tolerated, causing few side effects.